Wavelength Pharmaceuticals
Formerly Chemagis, Perrigo API, Perrigo
Active Pharmaceutical Ingredients
Startup Acquired Health Tech & Life Sciences Est. 1987 Acquired
Total Raised
Undisclosed
Acquired
Last Round
Undisclosed
1 rounds
Team
4
51-200 employees
Confidence
90/100
News
8
articles
Patents
1
About
Wavelength Pharmaceuticals develops and manufactures active pharmaceutical ingredients and select finished dosage forms. The company focuses on differentiated products that require sophisticated manufacturing processes. Its solution provides customers with comprehensive technical support and in-depth regulatory support across the entire product lifecycle, from project inception to commercial production. Wavelength Pharmaceuticals core strengths include complex chemistry, innovative process development, crystalline forms, and particle design. It tailors customized solutions to meet individual customer requirements, including full spectrum API CDMO services from preclinical grams to multi-ton commercial quantities.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Materials & SubstancesBiologicals
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
pharmaceuticalsapiallergysleep-disordersgastroenterologyalzheimers-diseasesupply-chainrespiratorycancerdermatology
Funding & Events
Nov 2017
Exit $110M
Jul 2022
Non-equity Undisclosed
BIRD Foundation (Lead)
Feb 2021
M&A Undisclosed
Feb 2021
M&A Undisclosed
Dec 2021
Exit Undisclosed
News (8)
Sep 14, 2022 · www.prnewswire.com
growth-positive
On Demand Pharmaceuticals and Wavelength Pharmaceuticals Awarded BIRD Foundation Grant
Investment
Aug 17, 2021 · www.prnewswire.com
growth-positive
Tikun olam-Cannbit continues to expand its footprint in the pharmaceutical arena
Partners
Feb 18, 2021 · www.businesswire.com
Wavelength Pharmaceuticals Further Strengthens Its Global Supply Chain with Acquisition of Vanamali Organics
Apr 20, 2020 · www.businesswire.com
Wavelength Pharmaceuticals Expands Supplies of Key Drug Ingredients for Critically Ill COVID-19 Patients
Apr 20, 2020 · www.contractpharma.com
growth-positive
Wavelength Ups API Production for Essential Respiratory Meds
CustomersExpand
Nov 29, 2017 · www.businesswire.com
Wavelength Pharmaceuticals Names Iftach Seri as Chief Executive Officer and Tami Cohen as Chief Financial Officer
Nov 22, 2017 · en.globes.co.il
growth-positive
Perrigo completes sale of Israeli unit Chemagis for $110m
Acquisition
Aug 10, 2017 · en.globes.co.il
growth-positive
SK Capital buys Perrigo's Israel unit Chemagis for $110m
AcquisitionInvestment
Details
Product Stage
Released
Employees
51-200
Exact Count
95
District
Center District,South District
Founded
1987
Registrar
515666485
Crunchbase
perrigo-api
Locations
Ramat Hovav, Israel
Shlomo Shmeltzer Road 94, Petah Tikva, Israel
Ronda del General Mitre, 126, Barcelona, Spain
1700 Route 23, Wayne, NJ 07470, USA
Links
Website
LinkedIn
Facebook
Careers
Admin
Last Update
Oct 6, 2024
Verified by
Natalia Golczar
Missing
funding rounds, markets, not claimed
Team (4)
Iftach Seri
CEO & Board Member
Sarah Isaacs
VP Quality, Regulatory & Compliance
Benzion Dolitzky
VP R&D
Amit Kalimi
Head of Operations
Internal
Created by
Yanina Wainscheinker (yanina.wain@gmail.com)
Created
2018-06-18T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Acquired by SK Capital Partners on Nov, 2017